Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
about
NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin RemodelingMicro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemiaMolecules that target nucleophosmin for cancer treatment: an updateFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Zebrafish as a model for leukemia and other hematopoietic disordersRole of HOXA9 in leukemia: dysregulation, cofactors and essential targetsA novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclastsCombined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.Deciphering the folding transition state structure and denatured state properties of nucleophosmin C-terminal domain.Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish.Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro.Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell typeNucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNAFLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from IndiaSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicMonoclonal antibodies against nucleophosmin mutants: potentials for the detection of acute myeloid leukemia.Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent.Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin.Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaSpontaneous remission in three cases of AML M5 with NPM1 mutation.Identification of two novel NPM1 mutations in patients with acute myeloid leukemiaExamination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland.Nucleophosmin, a critical Bax cofactor in ischemia-induced cell deathQuizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.Nucleophosmin Mutations Induce Chemosensitivity in THP-1 Leukemia Cells by Suppressing NF-κB Activity and Regulating Bax/Bcl-2 Expression.Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.The role of HOX genes in normal hematopoiesis and acute leukemia.Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.The utility of immunohistochemistry for providing genetic information on tumors.Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.Targeted therapy of acute myeloid leukemia.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Taspase1: a 'misunderstood' protease with translational cancer relevance.Molecular and cytogenetic abnormalities in acute myeloid leukemia: review and case studies.Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.
P2860
Q21296810-76A211B6-74EC-4591-9DFD-39A544CA2282Q24612217-A3F15070-3F4F-43BB-82DE-80CAE0232E7AQ26750653-C95804F9-F976-4F2B-917B-67570191964CQ27851545-62F20C6C-D515-4FA0-A5FD-EA2463138496Q27851909-D1A4DE3B-E644-47D9-9652-9DEBD44BF518Q28081638-A6F5630A-1C67-45B3-8961-6233C87EE114Q28082027-AD94BB07-A085-4440-9902-AEC6B79A1ABFQ28543087-3BCF000D-ADE5-4D76-B9BF-12D50CF99A4CQ33647411-C6AED04E-CCCE-49AA-8D31-E60578C93265Q33777703-3CECEE04-5561-4EB2-8A38-73B8DE8EB0F7Q33800539-A6E82BFF-D007-447B-B0CA-309F7413F25EQ33806096-3DA0D886-F545-4A0F-8103-0C1A1F8EEDC9Q33861884-4F2893AC-B4E3-450A-B0CF-E845521C0A94Q33980633-2E1EC715-76B1-4B40-AF83-4D165EA579E1Q34035133-D334794C-E0A0-45FE-8B16-788E8F5EF5E5Q34494573-6097C1C0-B662-4036-8E4A-6D1BAFB5AE6EQ34817365-31CECFB4-9A5B-4FF1-8C60-01C5E0410F86Q35001805-55D11E31-D567-4B35-B861-97A12DAA1006Q35596909-E754EFAC-2F01-4A2E-9F2A-52BAB17DB33AQ35796956-C84262D9-635A-4AD1-A014-EF2B37ED293FQ36143099-2ABBFBC4-F4D8-4DF5-ACBA-4EDC5D00BB4EQ36206410-DC3DDEBD-DD6B-477E-8707-68628496A9CFQ36270821-28CE63E3-2FA5-4273-A863-9A870CF9C9D0Q36502698-EF299459-0664-4E64-9612-9A69DF650725Q36582324-85EC86D2-204D-41C9-B380-4EDE44443FFFQ36826808-6CA1BE7E-751F-4C5F-BA72-B524DE85EAEDQ37052890-35153E82-8554-4E53-9928-3AF56FF13565Q37514072-4F332BBF-C858-4899-9356-EBC82D971D79Q37603441-F3186EA5-34FB-412A-9011-00091599B32AQ37688379-36E47AE9-0ADB-47A5-9A2F-1E900120C60CQ38065068-910CEC97-3BCD-4F3D-831E-3997B0E77D81Q38084251-A468DECF-9F5A-4E62-A2DC-FE458D200AF2Q38142818-8822DE55-593C-4962-AD41-B237FB766CB5Q38245417-85C655E6-C7DD-42ED-8D08-048A8DBE37B6Q38333251-DB17E7E5-5493-4559-9756-DA3AB281DA19Q38428692-BE60561D-108F-4AE4-84AC-FF005E32DC00Q38666356-35285264-B026-4B53-9B1E-CA79A66827EFQ38694679-DB9EF2A7-0436-4EC7-9454-592C24EBB958Q38722849-62420E71-C1E3-4BC0-BFBA-2094F708A99AQ38724800-58F51100-DA0A-4681-8D96-1805EB6CB388
P2860
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Altered nucleophosmin transpor ...... sis and clinical implications.
@en
Altered nucleophosmin transpor ...... sis and clinical implications.
@nl
type
label
Altered nucleophosmin transpor ...... sis and clinical implications.
@en
Altered nucleophosmin transpor ...... sis and clinical implications.
@nl
prefLabel
Altered nucleophosmin transpor ...... sis and clinical implications.
@en
Altered nucleophosmin transpor ...... sis and clinical implications.
@nl
P2093
P2860
P356
P1433
P1476
Altered nucleophosmin transpor ...... asis and clinical implications
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2009.124
P577
2009-06-11T00:00:00Z